Skip to main content Skip to footer

News

News

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

May 26, 2026

50/50 strategic collaboration will develop up to three radiopharmaceutical programs. Innovation and investment continue to...

Read More about Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
News

Niowave Breaks Ground on New $75 Million Production Facility to Advance Targeted Cancer Therapies

May 21, 2026

The new facility positions Niowave to meet global demand for Actinium‑225 and support growing pipeline...

Read More about Niowave Breaks Ground on New $75 Million Production Facility to Advance Targeted Cancer Therapies
News

Niowave and Novartis Enter Global Actinium-225 Supply Agreement to Advance Next-Generation Cancer Therapies

February 11, 2026

Niowave has entered into a new agreement with Novartis to supply Actinium-225, a highly promising...

Read More about Niowave and Novartis Enter Global Actinium-225 Supply Agreement to Advance Next-Generation Cancer Therapies
News

Niowave Marks 20 Years of Advancing Medical Radioisotope Production

January 23, 2026

Lansing-based company reflects on two decades of innovation, evolving from equipment manufacturing to scaling next-generation...

Read More about Niowave Marks 20 Years of Advancing Medical Radioisotope Production
News

Niowave Expands Global Supply Agreement with AstraZeneca to Deliver Actinium-225 for Next-Generation Cancer Therapies

December 19, 2025

Niowave will expand its agreement to supply Actinium-225, a highly promising medical isotope, to AstraZeneca

Read More about Niowave Expands Global Supply Agreement with AstraZeneca to Deliver Actinium-225 for Next-Generation Cancer Therapies